Alpha-1 antitrypsin deficiency (AAT) is a hereditary recessive autosomal disease caused by mutations in the AAT gene. This disease is characterized by abnormally low AAT concentrations in plasma, which, in its homozygote form, carries a high risk for the development of early pulmonary emphysema and liver damage. Since the end of the 1980s augmentation therapy with AAT from human plasma has been available for specific treatment of emphysema due to AAT deficiency. Intravenous augmentation therapy has been demonstrated to be safe and weekly infusions of AAT have resulted in plasma AAT concentrations above those considered protective for the lungs. However, life-long weekly infusions are not well accepted by patients, therefore pharmacokinetic studies have been performed to try to individualize the therapeutic regimen in order to obtain adequate trough serum AAT levels with prolonged intervals of administration. Therapeutic regimens administered every two weeks appear to be safe and result in adequate trough serum concentrations, but less-frequent administrations result in trough levels below the target. Alpha-1-antitrypsin deficiency is largely unrecognized and underdiagnosed. The foundation of national and international registries is a valid strategy to increase awareness about the disease and collect information about the natural history of this deficiency. Furthermore, the identification of a large number of patients will allow the development of new clinical trials aimed at finding better treatments for this infrequent condition.
Introduction
Alpha-1-antitrypsin (AAT) is the main antiprotease in human serum. Its deficiency is a genetic disorder characterized by reduced serum and lung concentrations of this protein which predispose to early-onset emphysema, especially in smokers. Currently, intravenous augmentation therapy with pooled human plasma AAT is the only available specific therapy for AAT deficiency approved by the Regulatory Agencies. Augmentation therapy has been shown to have biochemical efficacy in treating patients with emphysema due to severe AAT deficiency [Stoller and Aboussonan, 2004; Stoller et al. 2002] . Nonetheless, the clinical efficacy in slowing the progressive deterioration of lung function or the destruction of lung parenchyma is still under investigation [ATS/ERS Statement, 2003 ]. In the present review the fundamental aspects of augmentation therapy, including biochemical and clinical efficacy and safety are described. The biochemical characteristics of the commercial preparations available for intravenous administra-Correspondence to: tion are also briefly reviewed.
Marc Miravitlles
The high cost of therapy and the inconvenience for patients due to the frequent administration of intravenous treatment have led to the analysis of other therapeutic regimens for augmentation therapy in patients with AAT deficiency with the objective of prolonging the period between administrations while maintaining adequate or so-called 'protective' serum levels of the protein. In this regard, new pharmacokinetic studies have allowed the determination of the serum concentrations obtained with regimens other than the recommended schedule of 60 mg/Kg/week [Soy et al. 2006 ]. Finally, the importance of gathering information about large groups of patients in national and international registries will be discussed. These large databases will allow better knowledge of the natural history of the disease and the design of new clinical trials aimed at evaluating alternative treatments for this infrequent condition [Stockley et al. 2007 ].
Basic aspects of augmentation therapy, biochemical efficacy
Medical treatment of patients with emphysema associated with AAT deficiency should include the same pharmacological and nonpharmacological measures as those used to manage AAT-replete COPD patients [Miravitlles, 2005] . A purified preparation of AAT derived from donor plasma has been available for intravenous administration since 1987 [Wewers et al. 1987] . It has been shown that the infused preparation maintains its enzyme inhibitory activity in both plasma and bronchoalveolar lavage. Moreover, since a direct correlation exists between plasma concentrations of AAT and its pulmonary activity [Hubbart et al. 1988 ], treatment can be monitored by measuring minimum plasma concentrations at steady state (C min ), also called trough concentrations. C min are the concentrations obtained after a steady state has been reached and before the subsequent infusion [Wewers et al. 1987 ]. On the basis of data from epidemiological studies, it has been concluded that a C min of 0.8 g/L determined by radial immunodiffusion or 0.5 g/L determined by nephelometry is a level that can provide adequate protection for the lungs comparable to that of normal nonsmokers [ATS/ERS Statement, 2003 ]. As the half-life of infused AAT is between 4 and 5 days, the regimens initially tested were based on weekly infusions [Barker et al. 1994; Wewers et al. 1987] . The dosage regimen recommended in the manufacturer's prescribing information sheet is still 60 mg/Kg/week and this is the dose approved by the Food and Drug Administration (FDA) and the European Agency for Evaluation of Medicinal Products (EMEA) [Vidal et al. 2006b; ATS/ERS Statement, 2003 ]. However, given the obvious disadvantages of weekly administration for a lifetime treatment, infusions every 14, 21, and 28 days have also been assessed. In fact, data from the National Heart, Lung and Blood Institute (NHLBI) Registry showed that only 33% of patients under replacement therapy were receiving weekly infusions at the end of follow-up [Stoller et al. 2003 ]. Pharmacokinetc (PK) studies have allowed the investigation of different dosing regimens of augmentation therapy in patients with AAT deficiency, the results of which will be discussed extensively in the following sections. Briefly, it was observed that the PK properties of infused AAT at the regimens of 120 mg/Kg/ days and 180 mg/Kg/21 days did not achieve equivalent total trough AAT concentrations compared with the recommended dose of 60 mg/Kg/7 days. However, regimens of 50 mg/Kg/7 days and 120 mg/Kg/14 days seemed to be effective in maintaining total AAT trough concentrations above 0.5 g/L during the entire interval in roughly 85% of patients in the latter and 100% in the former. In contrast, 3-weekly and monthly administration of replacement therapy required very high doses to achieve the desired threshold for most patients [Soy et al. 2006 ] (Table 1) .
Clinical efficacy
The slow progression of pulmonary emphysema requires large and prolonged clinical trials to demonstrate any significant efficacy in changing the course of the disease. The characteristics of AAT deficiency make it extremely difficult to perform such a large trial. The only published randomized double-blind placebocontrolled clinical trial has compared treatment with human AAT and placebo using a dosage regimen of 250 mg/Kg/28 days [Dirksen et al. 1999 ]. This trial, including 58 patients treated for 3 years, revealed no significant differences in the evolution of lung function, but the patients who received AAT presented an annual loss of lung density measured by computed tomography of 1.50 g/L compared to a 2.57 g/L loss observed in patients receiving placebo ( p = 0.07) [Dirksen et al. 1999 ].
All other data in the literature concerning the effectiveness of augmentation therapy derive from comparative cohort studies [Stoller and Aboussonan, 2004 ]. These studies have revealed a significant reduction in the decline in FEV 1 in patients with an FEV 1 between 30% and 60% of the predicted value [Seersholm et al. 1997; Wencker et al. 2001] . Moreover, data from the NHLBI in the USA on 1048 patients followed for between 3.5 and 7 years revealed a significant 36% reduction in mortality among patients receiving augmentation therapy continuously or intermittently as compared to patients not receiving such therapy ( p = 0.02) [The Alpha-1-Antitrypsin Deficiency Registry Study Group, 1998 ].
An interesting effect of augmentation therapy is that it may possibly give protection against bronchial infections, an important consideration given the high prevalence of bronchiectasis in †All the concentrations referred to are trough levels before the subsequent dose. ‡The protective threshold value is considered to be 80 g/L measured by radial immunodiffusion and 50 g/L by nephelometry1.
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this population [Miravitlles et al. 1999a ] and the impact of exacerbations on health status in AATdeficient individuals [Needham and Stockley, 2005] . The results of one observational study in which patients were interviewed about the frequency of exacerbations the year prior to augmentation therapy compared to the frequency reported the first year after initiation therapy have suggested that exacerbations can be prevented with augmentation [Lieberman, 2000] .
These results should be interpreted with caution, since this was not a randomized trial and other factors might account for the reduction in the frequency of exacerbations. However, there is some rationale behind this finding. The restoration of the protease/antiprotease imbalance and reduction of inflammation in the airways of patients receiving augmentation therapy may be, at least in part, responsible for a decreased susceptibility of exacerbations .
It is difficult to observe the effect of augmentation therapy in patients with severe disease (FEV 1 < 30%) because these patients often die or undergo lung transplantation before a sufficiently long follow-up period has elapsed [The Alpha-1-antitrypsin Deficiency Registry Study Group, 1998] . Neither is it possible to evaluate the effect of this treatment in patients with mild disease (FEV 1 > 60%), as bias by indication exists. The few patients who receive treatment at such an early stage are index cases with particularly serious symptoms or patients experiencing accelerated loss of lung function, while the patients in the control group who are not receiving treatment tend to be nonindex cases who are not receiving treatment precisely because they are asymptomatic or have stable lung function [Wencker et al. 2001 ; The Alpha-1-antitrypsin Deficiency Registry Study Group, 1998 ].
Safety of augmentation therapy
Intravenous infusion of human AAT for the chronic treatment of emphysema caused by AAT deficiency has been shown to be very safe. This treatment was first administered in 1987, and no acute reactions were observed [Wewers et al. 1987] . It should be noted that no adverse reactions to protein overload have been observed after regular long-term monthly administration of high doses of AAT [Dirksen et al. 1999; Hubbard et al. 1988 ]. In the largest database of adverse effects (the NHLBI Registry) the frequency of such effects was 0.02 per patient per month, but only 9% of these were considered serious and only 1.7% required emergency department attention or led to hospitalization. Up to 85% of patients reported no adverse effects. The most common adverse effects were headache (47%), dizziness (17%), nausea (9%), and dyspnea (9%). No cases of transmission of human immunodeficiency virus, prion diseases, or hepatitis A, B, C, or delta have been reported.
Patients who received weekly infusions reported a higher frequency of adverse effects, some of which were considered to be serious [Stoller et al. 2003 ].
Products available for intravenous administration
There are currently three AAT preparations derived from human plasma available for intravenous administration:
• Prolastin (Talecris Biotherapeutics, USA), which is supplied in powder form for reconstitution in 50 mL vials. After reconstitution, each vial contains at least 20 mg/mL providing a total of 1000 mg of AAT. • Trypsone (Instituto Grifols, S.A Barcelona, Spain), or Aralast (Baxter, USA). Both are the same product obtained from human plasma by the same procedure. They are supplied in powder form for reconstitution in 25 or 50 mL vials. After reconstitution, each vial contains at least 20 mg/mL providing a total of 500 mg or 1000 mg of AAT, respectively. • Zemaira (CSL Behring, USA). Zemaira® is supplied as a powder to be administered by the intravenous route. Its specific activity is ≥0.7 mg of functional AAT per milligram of total protein. Following reconstitution of 20 ml, each vial contains approximately 1000 mg of functionally active AAT.
In the only comparative randomized, doubleblind clinical trial published to date, Aralast/ Trypsone achieved a C min in serum equivalent to the levels obtained with Prolastin. The antielastase capacity of the AAT levels in bronchoalveolar lavage was also equivalent for both preparations in a small sample of patients [Stoller et al. 2002] .
In some countries such as Spain, treatment is administered in the day hospital units of hospitals. The product for infusion must be prepared by the hospital pharmacy after the patient has arrived to the center and must be infused as soon as possible because the period of activity after reconstitution is between 3 and 4 hours. The continuous perfusion rate should be under 0.08 mL/kg/min. In other countries such as the United States and Germany, the treatment can be administered at home by the family physician or the community nurse. The demonstrated safety of the intravenous infusions of AAT allows home administration; however, since sporadic cases of anaphylaxis have been reported, it is advised to administer the first 3 to 4 doses in a hospital environment.
Criteria for initiating augmentation therapy
Augmentation therapy is only indicated in patients with pulmonary emphysema secondary to AAT deficiency. It has no effect on liver disease associated with this deficiency. The possible benefits of this therapy in the management of other less common manifestations of AAT deficiency, Review such as panniculitis, have not been sufficiently documented.
Augmentation therapy should only be prescribed to patients with severe AAT deficiency, a PiZZ phenotype, or a rare deficient variant and functional evidence of pulmonary emphysema [Miravitlles et al. 1999b ]. In nonindex cases (those in which the deficiency is diagnosed through family screening rather than as a result of respiratory symptoms), accelerated loss of lung function for at least 1 year should be demonstrated [Vidal et al. 2006b ].
This therapy is not indicated in heterozygous PiMZ or PiSZ patients. Owing to the fact that blood derivatives may contain traces of IgA, and patients with IgA deficiency may have circulating anti-IgA antibodies, the presence of IgA deficiency must be ruled out before augmentation therapy is started. The treatment criteria are shown in Table 2 .
Routine vaccination against hepatitis A and B before treatment is not routinely recommended at this time [ATS/ERS Statement, 2003] .
Recommended regimens of administration
No single dosage regimen exists for AAT augmentation therapy. The prescribing information sheets for the products currently available recommend, a dosage of 60 mg/Kg/week in the absence of any other medical indication, because this is the best documented regimen, based on the halflife of the infused AAT, and the extensive studied performed [Stoller et al. 2003; Schwaiblmair et al. 1997; Wewers et al. 1987 ]. However, the safety and efficacy of other regimens have been demonstrated in several studies. In total, 67% of patients in the USA, whose data is on the NHLBI registry, have been administered therapy at intervals other than 1 week [Stoller et al. 2003 ]. In light of these data, together with the difficulties most patients have with a lifetime weekly regimen and the demonstration that monthly administration produced very low C min values [Dirksen et al. 1999; Hubbard et al. 1988; Miravitlles et al. 1994] , the Spanish Registry recommended the use of a dosage of 180 mg/Kg/21 days as an alternative to the weekly regimen [Vidal et al. 2006b; Miravitlles et al. 1998 ]. The three-weekly regimen has been widely used in Spanish over the last 10 years with no incidence of significant side effects [Vidal et al. 2006b; Miravitlles et al. 1999b ]. New pharmacokinetic studies have demonstrated that the administration of 50 mg/Kg/7 days and 120 mg/Kg/14 days have been shown to produce C min values above the protective threshold level in over 90% of patients [Vidal et al. 2006a; Soy et al. 2006 ]. Administration of 180 mg/Kg/ 21 days produces protective C min values for approximately 85% of the interval between doses. The trough concentrations obtained by the different therapeutic regimens are depicted in Table 3 . One of the main observations derived from PK studies is that bi-or three-weekly doses necessary to obtain adequate nadir concentrations of AAT are not the result of simply multiplying the weekly dose by 2 or 3 [Soy et al. 2006 ]. Due to the PK characteristics of the infused AAT, the doses required to obtain protective C min values after three-weekly administrations represent a mean increase of 74% over the dose required with weekly administration [Soy et al. 2006 ]. This increase is difficult to justify given the high cost and limited availability of the product. One solution to try to circumvent this problem is to calculate the dose required to provide protective C min values for at least 85% of the time between dose. Treatment administered every 21 days is called dose 21/85 or D21/85. To reach this goal a small mean increase of only 13% over the total weekly dose is needed [Soy et al. 2006 ]. We need to bear in mind that the impact of leaving the lungs 'unprotected' for 3 out of every 21 days is unknown, and the ideal treatment should provide complete coverage over the entire period between doses.
In the absence of conclusive studies on the relationship between clinical efficacy and pharmacokinetic measurements, dosage regimens must be chosen on a patient-by-patient basis and are the result of a compromise between biochemical efficacy, the patient's expectations and availability, and the possibilities of the day care center.
Systematic measurements of C min values are not recommended, because the interpretation of the findings is complex and subsequent adjustment of the dosage regimen would require an individual pharmacokinetic analysis. When it is suspected that a dose adjustment is needed, the necessary study should be undertaken by a research center with expertise in pharmacokinetics. 
Other treatments for patients with AAT deficiency
Recommendations for the management of patients with emphysema secondary to AAT deficiency are similar to those that apply to patients with COPD who have normal AAT levels. These patients should receive routine treatment with inhaled bronchodilators supplemented, when indicated, by inhaled corticosteroids. Annual influenza and pneumococcal vaccination is recommended because it has been demonstrated that these patients have a good specific antibody response [Miravitlles et al. 1999a ].
Exacerbations in AAT deficient patients are characterized by an excess of elastase activity, being much more marked than in AAT-replete COPD patients [Hill et al. 1999] . For this reason, exacerbations must be treated energetically and as early as possible by increasing the bronchodilator dosage, administering short courses of oral corticosteroids, and prescribing antibiotics when changes are observed in the quantity or characteristics of sputum.
Supplemental oxygen should be considered when the case fulfills the conventional criteria for this treatment. Pulmonary rehabilitation should be offered to patients with functional impairment. Lung transplantation is an option that can be offered to selected patients with severe disease. The results of lung volume reduction surgery in patients with AAT deficiency have been inconclusive, and these patients are not considered to be ideal candidates for this intervention owing to the morphological characteristics of their pulmonary impairment [Cassina et al. 1998 ].
As a general rule, a quarterly visit to the treating physician and simple spirometry is recommended. Static lung volumes and carbon monoxide transfer should be measured once a year. Arterial blood gas analysis and chest computed tomography should be performed when justified by clinical changes. A proposed schedule of follow-up for patients with emphysema due to AAT deficiency is presented in Table 4 .
Alfa-1-antitrypsin deficiency, an underdiagnosed disease
The need for increasing awareness and the lack of consensus criteria for treatment and follow up in Spain led to the creation of the Spanish Registry of Patients with AAT Deficiency in 1993, within the working area of Respiratory Insufficiency and
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Sleep Disorders (IRTS) of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) [Miravitlles et al. 1998 ]. This registry also provides advice on aspects related to the diagnosis, the treatment and the follow up of patients with AAT deficiency and participates in international investigation projects.
The low prevalence of AAT deficiency makes the creation of international registries necessary as suggested by the World Health Organization (WHO) in its information bulletin in 1997 [Memoranda WHO, 1997] . Only in this way can a large enough population of patients be gathered to perform clinical trials aimed at determining the efficacy of new treatments for this disease. Following these guidelines, in 1999 the Spanish Registry became a member of the Alpha-1 International Registry (AIR) which is currently made up of the association of 21 national registries from four continents [Stockley et al. 2007; Luisetti et al. 2002] Although the diagnosis of the deficiency is not difficult and its detection is a type A recommendation in all guidelines [ATS/ERS Statement, 2003 ], all the studies undertaken have demonstrated that diagnosis is not performed early enough and underdiagnosis is a constant [Blanco et al. 2007; Campos et al. 2005; Stoller et al. 2005 ]. The Spanish registry has carried out a screening campaign for this deficiency in patients with COPD with dried blood spots [De la Roza et al. 2005 , which has allowed the analysis of more than 2,000 samples and the diagnosis of 8 individuals with a severe deficiency [De la Roza et al. 2005] . Taking into account the expected number of patients with COPD in Spain, it can be said that there must be 5,000 patients with COPD due to a severe AAT deficiency. These numbers are somewhat lower than the number of homozygote PiZZ individuals expected on epidemiological calculations derived from studies analyzing the gene frequency in the population [Blanco et al. 2007 ]. These differences are, in part, due to the penetration of the gene, that is, the variability in the development of COPD in homozygotic carriers according to different factors such as smoking or other genetic determinants of risk [De Meo et al. 2007 ] which condition the fact that not all the PiZZ individuals develop emphysema at a similar age or with a similar severity. Nonetheless, the most optimistic estimations suggest that the Spanish registry only includes 6% of the probably existent cases in Spain [Lara et al. 2007 ]. In view of these results, the new SEPAR guidelines on treatment of AAT deficiency insist on the need for performing the determination of serum AAT in all patients with COPD [Vidal et al. 2006b ]. Similar case-detection programs have been carried out in other countries with different protocols and results [Bals et al. 2007; Corda et al. 2006; Wencker et al. 2002; Luisetti et al. 1999] . Despite the differences between them, these initiatives have been useful in increasing the awareness of the disease among healthcare professionals and detecting new cases at an earlier stage when medical intervention can offer better opportunities and improve the quality of life of these patients.
